title: Relationship between HCV dynamics and sustained virological responses in chronic hepatitis C genotype 1b patients treated with telaprevir-based triple therapy.
abstract: OBJECTIVE
  This study investigated the relationship between hepatitis C virus (HCV) dynamics and sustained virological response (SVR), as well as the efficacy of an extended treatment with telaprevir-based triple therapy among patients with chronic hepatitis C genotype 1b.
  
  
  METHODS
  Among 220 patients receiving triple therapy for 24 weeks, the SVR rate was analyzed at each time point at which HCV RNA became undetectable. The SVR rates in the patients who did not achieve a rapid virological response (RVR) were compared with those in 27 patients who received triple therapy for 48 weeks.
  
  
  RESULTS
  The SVR rates of interleukin 28B (IL28B) TT and non-TT patients were 100 versus 66.7% after 1 week, 97.6 versus 72.2% after 2 weeks, 95.2 versus 84.2% after 3 weeks, 93.1 versus 72.2% after 4 weeks, 76.9% versus 11.1% after 6 weeks, and 88.9 versus 14.3% after 8 weeks, respectively. All of the IL28B TT patients who showed undetectable HCV RNA levels until week 8 achieved an SVR. In contrast, the SVR rates in the IL28B non-TT patients who did not achieve RVR with 24 and 48 weeks of treatment were 11.8 and 62.5%, respectively (P=0.017).
  
  
  CONCLUSIONS
  These results suggest that an SVR can frequently be achieved by IL28B TT patients, even with 24 weeks of treatment, when HCV RNA remains undetectable until week 8, and also that IL28B non-TT patients should have RVR values to achieve an SVR with 24 weeks of treatment. The SVR rate was low in IL28B non-TT patients treated for 24 weeks who did not achieve an RVR; however, it could increase when the treatment duration was extended to 48 weeks.
authors.affiliation: aDivision of Gastroenterology, Nippon Medical School Chiba Hokusoh Hospital, Inzai bDivision of Gastroenterology and Hepatology, Shinmatsudo Central General Hospital, Matsudo, Chiba cCore Research Facilities for Basic Science, Research Center for Medical Sciences, Jikei University School of Medicine, Minato-ku dJikei University School of Medicine Katsusika Medical Center, Division of Gastroenterology and Hepatology, Katsushika-ku eDivision of Gastroenterology and Hepatology, Nippon Medical School, Bunkyo-ku, Tokyo, Japan.
authors.forename: Ai
authors.initials: A
authors.lastname: Nakagawa
authors.forename: Masanori
authors.initials: M
authors.lastname: Atsukawa
authors.forename: Akihito
authors.initials: A
authors.lastname: Tsubota
authors.forename: Noritomo
authors.initials: N
authors.lastname: Shimada
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Abe
authors.forename: Chisa
authors.initials: C
authors.lastname: Kondo
authors.forename: Norio
authors.initials: N
authors.lastname: Itokawa
authors.forename: Taeang
authors.initials: T
authors.lastname: Arai
authors.forename: Satomi
authors.initials: S
authors.lastname: Hashimoto
authors.forename: Yoko
authors.initials: Y
authors.lastname: Matsushita
authors.forename: Takeshi
authors.initials: T
authors.lastname: Fukuda
authors.forename: Katsuhisa
authors.initials: K
authors.lastname: Nakatsuka
authors.forename: Katsuhiko
authors.initials: K
authors.lastname: Iwakiri
authors.forename: Chiaki
authors.initials: C
authors.lastname: Kawamoto
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Aizawa
authors.forename: Choitsu
authors.initials: C
authors.lastname: Sakamoto
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D004359:Drug Therapy, Combination; D005260:Female; D005838:Genotype; D016174:Hepacivirus / Q000187:drug effects* / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics / Q000821:virology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D007372:Interferons; D007378:Interleukins / Q000235:genetics; D007564:Japan; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000627:therapeutic use*; D011092:Polyethylene Glycols / Q000627:therapeutic use; D012367:RNA, Viral / Q000097:blood; D011994:Recombinant Proteins / Q000627:therapeutic use; D012254:Ribavirin / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome; D019562:Viral Load; D055815:Young Adult; D000095022:Interferon Lambda
chemical_list: D000998:Antiviral Agents; D015415:Biomarkers; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D007372:Interferons; D007378:Interleukins; D009842:Oligopeptides; D011092:Polyethylene Glycols; D012367:RNA, Viral; D011994:Recombinant Proteins; D012254:Ribavirin; C000624353:interferon-lambda, human; D000095022:Interferon Lambda; C486464:telaprevir; C417083:peginterferon alfa-2b